Investigating how TIGIT helps protect the heart during cancer immunotherapy
TIGIT upholds peripheral tolerance in ICI-myocarditis
This study is looking at how a protein called TIGIT might help protect the heart from damage caused by cancer treatments known as immune checkpoint inhibitors, which can sometimes lead to heart problems in patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10995605 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a protein called TIGIT in preventing heart damage caused by immune checkpoint inhibitors (ICIs), which are used in cancer treatment. While ICIs can effectively target tumors, they may also trigger harmful immune responses that affect the heart, leading to a serious condition known as ICI-myocarditis. The study will explore how TIGIT signaling interacts with other immune pathways to maintain heart health during cancer therapy. By examining these mechanisms in laboratory models, the research aims to identify potential strategies to mitigate heart-related side effects in cancer patients receiving ICIs.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are receiving immune checkpoint inhibitors and are at risk for heart-related side effects.
Not a fit: Patients who are not undergoing cancer treatment or those who do not have a risk of ICI-myocarditis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for protecting the heart in cancer patients undergoing immunotherapy.
How similar studies have performed: Previous studies have shown that targeting immune pathways can effectively reduce adverse effects in cancer treatments, suggesting potential success for this approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Jaime, Camille — Johns Hopkins University
- Study coordinator: Jaime, Camille
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.